Global healthcare major Abbott has partnered with Novo Nordisk India to commercialize Extensior®, broadening access to semaglutide (Ozempic®) for advanced type 2 diabetes management in India. Under the agreement, Abbott will market Novo Nordisk’s semaglutide under the brand name Extensior®, leveraging its strong nationwide distribution network.
Extensior® is a second brand of Ozempic®, the world’s most prescribed GLP-1 receptor agonist. Approved as an adjunct to diet and exercise for adults with type 2 diabetes, it delivers significant HbA1c reduction, weight-loss benefits, and proven risk reduction of cardiovascular and kidney events. Semaglutide has been evaluated in over 44 clinical trials and 10 real-world studies and has nearly a decade of global use with more than 49 million patient years across products.
Kartik Rajendran, Managing Director, Abbott India Limited, said the partnership aims to expand access to high-quality, evidence-based therapies amid India’s fast-growing diabetes burden. Vikrant Shrotriya, Managing Director, Novo Nordisk India, described semaglutide as a major scientific advancement engineered through a precise r-DNA process. With over 100 million Indians living with diabetes and projections rising to 150 million by 2050, treatment demand is intensifying. In Kolkata, healthcare providers expect strong uptake of modern GLP-1 therapies as awareness grows and urban lifestyle-linked diabetes cases increase, reflecting wider national trends.